Overview

Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.
Phase:
N/A
Details
Lead Sponsor:
Ochsner Health System
Collaborator:
Astellas Pharma Global Development, Inc.
Treatments:
Adenosine
Regadenoson